← SynDRA
LIMKi3
SynDRA canonical compound SYN1245327 — structure-anchored drug synonym record
| Clinical phase | Preclinical |
|---|
| Primary target(s) | LIMK1 |
|---|
| Mechanism of action | LIM kinase inhibitor |
|---|
All known targets
Mechanisms of action (all sources)
- LIMK1 INHIBITOR
- LIMK2 INHIBITOR
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
Drug classes
- Protein Kinase Inhibitors
Cross-references
Synonyms
- LIMKi-3
- CHEBI:138670
- RefChem:924772
- BMS 5
- MFCD17019327
- C17H14Cl2F2N4OS
- LIMKI-3 (BMS-5)
- LIM Kinase Inhibitor I
- BMS-5?
- GTPL9839
- orb1302722
- SCHEMBL15543888
- EX-A934
- IVUGBSGLHRJSSP-UHFFFAOYSA-N
- GLXC-03070
- HMS3244I07
- HMS3244I08
- HMS3244J07
- HMS3743I19
- NDC24735
- BDBM50591090
- EBC-12896
- AKOS024458322
- CS-5617
- NCGC00263197-01
- NCGC00263197-02
- NCGC00263197-03
- AC-35331
- AS-16195
- DA-54927
- HY-18305
- S0185
- T4598
- EN300-115361
- Z1460124046
- LimKi 3
- N-{5-[1-(2,6-dichlorophenyl)-3-(difluoromethyl)-1H-pyrazol-5-yl]-1,3-thiazol-2-yl}-2-methylpropanamide
Look up LIMKi3 in the interactive SynDRA portal →